Stocklytics Platform
no data available for key stats

There's no data available for key stats

no data available for ratios/profitability stats

There's no data available for ratios/profitability stats

Fundamentals
Gross Profit-
Payout Ratio-
Industry average yield2.89%
Last Dividend pay date-
Dividend per share-
Dividend yield forecast-

Stock Analysis

Technicals

Summarizing what the indicators are suggesting.

—Strong Buy
—Buy
—Neutral
—Sell
—Strong Sell

Analyst rating

An aggregate view of professional's ratings.

—Strong Buy
—Buy
—Neutral
—Sell
—Strong Sell

Stock Performance

AURA-
US Healthcare Sector-
US Market-
warning

AURA / Market

AURA lose to the US Market which returned 0.03% over the last twenty four hours.
warning

AURA / Healthcare Sector

AURA lose to the US Healthcare sector which returned 2.60% over the last twenty four hours.

Aura Biosciences (AURA) Statistics

Aura Biosciences, Inc. (AURA) is a biotechnology company focused on the development of novel therapies for the treatment of cancer. The company is engaged in the research and development of its proprietary technology platform, which utilizes viral nanoparticles to deliver therapeutic agents directly to cancer cells. This approach has the potential to significantly improve treatment outcomes and reduce side effects compared to traditional chemotherapy. Aura Biosciences, Inc. is headquartered in Cambridge, Massachusetts.
When it comes to valuation metrics, Aura Biosciences, Inc. (AURA) has a market capitalization of $XX.XX billion. The company's enterprise value is $XX.XX billion. AURA is trading with a Price/Sales ratio of X.XX, which is higher than the industry average of X.XX. The company's Price/Book ratio is X.XX, which indicates that the stock may be overvalued. Aura Biosciences, Inc. has a Price/Earnings ratio of X.XX, which is lower than the industry average of X.XX. This suggests that the stock may be undervalued.
add Aura Biosciences to watchlist

Keep an eye on Aura Biosciences

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

How has Aura Biosciences (AURA) stock's performance compared to its sector and the market over the past year?

Over the past year, Aura Biosciences (AURA) has experienced a price change of . Compared to the Healthcare sector, which saw a change of 15.12%, Aura Biosciences has underperformed compared to its sector, indicating its relative standing within the Healthcare sector. Against the broader market's change of 23.87%, it has fallen short of the market average. This comparison highlights Aura Biosciences's performance relative to both its sector and the overall market over the last year.
help

What is the PE ratio of Aura Biosciences (AURA) stock?

The PE ratio for Aura Biosciences (AURA) is currently not available. This could be due to a variety of factors such as the company not having positive earnings at the moment or recent updates not being reflected.
help

What is the EPS of Aura Biosciences (AURA) stock?

The Earnings Per Share (EPS) for Aura Biosciences (AURA), calculated on a diluted basis, is -$1.73. EPS is a key indicator of a company's profitability, showing the portion of a company's profit allocated to each outstanding share of common stock.
help

What is the operating margin of Aura Biosciences (AURA) stock?

The operating margin for Aura Biosciences (AURA) is 0%. This metric represents the percentage of revenue that remains after paying for variable production costs, indicating the efficiency and profitability of the company's core business operations.
help

What is the EBITDA of Aura Biosciences (AURA) stock?

The EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) of Aura Biosciences (AURA) is -$91.84M. EBITDA is a widely used earnings metric to assess a company's operational efficiency and profitability before the impact of non-operating decisions such as financing, accounting, and tax environments.
help

How much debt does Aura Biosciences (AURA) have?

Aura Biosciences (AURA) has a total debt of $19.08M. The net debt, which accounts for cash and cash equivalents against the total debt, is -$6.32M.

Take Your Investments to a Whole New Level